Vitrolife AB (STO:VITR), an international medical device company, announced on Monday the decision by Barbro Fridén to step down as a member of the board of directors of the company, reportedly due to other future opportunities.
Fridén has been a member of the board of Vitrolife since 2010.
Vitrolife develops, produces and markets medical devices for assisted reproduction.
Headquartered in Gothenburg, Sweden, with offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, the UK and US, Vitrolife employs about 400 people and its products are sold in approximately 110 markets.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon